Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Below 200-Day Moving Average of $10.48

Theravance Biopharma, Inc. (NASDAQ:TBPH) crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $10.48 and traded as low as $9.74. Theravance Biopharma shares last traded at $9.87, with a volume of 588,807 shares changing hands.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on TBPH shares. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, August 8th. StockNews.com started coverage on Theravance Biopharma in a research report on Thursday, August 17th. They issued a “hold” rating on the stock.

Theravance Biopharma Stock Performance

The firm has a 50 day moving average of $9.78 and a two-hundred day moving average of $10.48. The stock has a market cap of $521.26 million, a P/E ratio of 0.87 and a beta of 0.43.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). Theravance Biopharma had a negative return on equity of 16.88% and a net margin of 1,694.17%. The firm had revenue of $13.75 million during the quarter, compared to the consensus estimate of $15.24 million. On average, sell-side analysts anticipate that Theravance Biopharma, Inc. will post -1.06 EPS for the current fiscal year.

Institutional Investors Weigh In On Theravance Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of TBPH. Principal Financial Group Inc. acquired a new stake in shares of Theravance Biopharma in the 1st quarter valued at $101,000. Acadian Asset Management LLC increased its position in shares of Theravance Biopharma by 51.6% in the first quarter. Acadian Asset Management LLC now owns 8,277 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 2,818 shares during the last quarter. Vanguard Group Inc. increased its position in Theravance Biopharma by 10.3% during the first quarter. Vanguard Group Inc. now owns 6,947,947 shares of the biopharmaceutical company’s stock worth $66,421,000 after buying an additional 648,124 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Theravance Biopharma by 3.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 402,640 shares of the biopharmaceutical company’s stock worth $3,850,000 after acquiring an additional 12,095 shares during the period. Finally, UBS Group AG boosted its holdings in shares of Theravance Biopharma by 45.0% during the first quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 1,101 shares during the period. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.